Apellis Pharmaceuticals, Inc. News Releases http://investors.apellis.com/ Apellis Pharmaceuticals, Inc. News Releases en Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress http://investors.apellis.com/news-releases/news-release-details/apellis-pharmaceuticals-presents-data-ongoing-apl-2-phase-2 CRESTWOOD, Ky. and WALTHAM Mass., June 15, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals  Inc. (Nasdaq: APLS ), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced Sat, 15 Jun 2019 10:32:00 -0400 Apellis Pharmaceuticals, Inc. News Releases 7786 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) http://investors.apellis.com/news-releases/news-release-details/apellis-pharmaceuticals-announces-inducement-grants-under-5 WALTHAM, Mass. and CRESTWOOD, Ky. , June 06, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals  Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced that, Thu, 06 Jun 2019 17:30:00 -0400 Apellis Pharmaceuticals, Inc. News Releases 7776 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) http://investors.apellis.com/news-releases/news-release-details/apellis-pharmaceuticals-announces-inducement-grants-under-4 WALTHAM, Mass. and CRESTWOOD, Ky. , May 24, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals  Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced that, on Fri, 24 May 2019 17:30:00 -0400 Apellis Pharmaceuticals, Inc. News Releases 7766 Apellis Pharmaceuticals to Present at Upcoming Investor Conferences http://investors.apellis.com/news-releases/news-release-details/apellis-pharmaceuticals-present-upcoming-investor-conferences-0 WALTHAM Mass. and CRESTWOOD, Ky. , May 17, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals  Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced Fri, 17 May 2019 08:00:00 -0400 Apellis Pharmaceuticals, Inc. News Releases 7741 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) http://investors.apellis.com/news-releases/news-release-details/apellis-pharmaceuticals-announces-inducement-grants-under-3 WALTHAM Mass. and CRESTWOOD, Ky. , May 13, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals  Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced that, on Mon, 13 May 2019 17:30:00 -0400 Apellis Pharmaceuticals, Inc. News Releases 7736 Apellis Pharmaceuticals Reports First Quarter 2019 Business Update and Financial Results http://investors.apellis.com/news-releases/news-release-details/apellis-pharmaceuticals-reports-first-quarter-2019-business Resumed Dosing in Phase 3 Geographic Atrophy Program Announced Innovative Collaboration & Financing with SFJ Pharmaceuticals ® Cash Position of $288.2 Million at Quarter-End WALTHAM Mass. and CRESTWOOD, Ky. , May 08, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals  Inc., (Nasdaq:APLS) a Wed, 08 May 2019 07:00:00 -0400 Apellis Pharmaceuticals, Inc. News Releases 7731 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) http://investors.apellis.com/news-releases/news-release-details/apellis-pharmaceuticals-announces-inducement-grants-under-2 WALTHAM Mass. and CRESTWOOD, Ky. , April 05, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals  Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced that, Fri, 05 Apr 2019 16:30:00 -0400 Apellis Pharmaceuticals, Inc. News Releases 7691 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) http://investors.apellis.com/news-releases/news-release-details/apellis-pharmaceuticals-announces-inducement-grants-under-1 WALTHAM Mass. , and CRESTWOOD, Ky. , March 22, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals  Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced that, Fri, 22 Mar 2019 16:30:00 -0400 Apellis Pharmaceuticals, Inc. News Releases 7686 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) http://investors.apellis.com/news-releases/news-release-details/apellis-pharmaceuticals-announces-inducement-grants-under-0 WALTHAM, Mass. and CRESTWOOD, Ky. , March 12, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals  Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced that, Tue, 12 Mar 2019 18:00:00 -0400 Apellis Pharmaceuticals, Inc. News Releases 7666 Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares http://investors.apellis.com/news-releases/news-release-details/apellis-pharmaceuticals-announces-closing-public-offering-common WALTHAM Mass. and CRESTWOOD, Ky. , March 11, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced Mon, 11 Mar 2019 12:01:00 -0400 Apellis Pharmaceuticals, Inc. News Releases 7661